Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016’, provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Focal Segmental Glomerulosclerosis (FSGS)

The report reviews pipeline therapeutics for Focal Segmental Glomerulosclerosis (FSGS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Focal Segmental Glomerulosclerosis (FSGS) therapeutics and enlists all their major and minor projects

The report assesses Focal Segmental Glomerulosclerosis (FSGS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Focal Segmental Glomerulosclerosis (FSGS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (FSGS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Complexa Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Retrophin Inc

Shire Plc

Variant Pharmaceuticals Inc

Complexa Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Retrophin Inc

Shire Plc

Variant Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Focal Segmental ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Focal Segmental Glomerulosclerosis (FSGS) Overview 6

Therapeutics Development 7

Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Overview 7

Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis 8

Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Development by Companies 9

Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Investigation by Universities/Institutes 10

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Focal Segmental Glomerulosclerosis (FSGS) - Products under Development by Companies 13

Focal Segmental Glomerulosclerosis (FSGS) - Products under Investigation by Universities/Institutes 14

Focal Segmental Glomerulosclerosis (FSGS) - Companies Involved in Therapeutics Development 15

Complexa Inc 15

Dimerix Bioscience Pty Ltd 16

GlaxoSmithKline Plc 17

Retrophin Inc 18

Shire Plc 19

Variant Pharmaceuticals Inc 20

Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Combination Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 30

(irbesartan + propagermanium) - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

CXA-10 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

losmapimod - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SHP-627 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

sparsentan - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

TM-5484 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

VAR-200 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects 44

Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products 45

Focal Segmental Glomerulosclerosis (FSGS) - Product Development Milestones 46

Featured News & Press Releases 46

Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board 46

Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 47

Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 48

Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016 49

Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis 51

Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 51

Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis 52

Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 53

Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 54

Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 54

Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 55

Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7

Number of Products under Development for Focal Segmental Glomerulosclerosis ...

List of Tables

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Complexa Inc, H2 2016 15

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 16

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by GlaxoSmithKline Plc, H2 2016 17

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Retrophin Inc, H2 2016 18

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Shire Plc, H2 2016 19

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Variant Pharmaceuticals Inc, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Assessment by Combination Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 29

Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects, H2 2016 44

Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7

Number of Products under Development for Focal Segmental Glomerulosclerosis ...

List of Figures

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports